

## PLASMAPHERESIS AS TREATMENT FOR HYPERLIPIDEMIC PANCREATITIS

Ramírez-Bueno A<sup>1</sup>., Salazar-Ramírez C<sup>2</sup>., Cota-Delgado F<sup>2</sup>., de la Torre-Prados M.V<sup>2</sup>.,  
Valdivielso P<sup>1,3</sup>.

<sup>1</sup>Unidad de Gestión Clínica de Medicina Interna y <sup>2</sup>Unidad de Gestión Clínica de Cuidados Críticos y Urgencias. Instituto de Biomedicina de Málaga (IBIMA), Hospital Universitario Virgen de la Victoria. <sup>3</sup>Departamento de Medicina y Dermatología, Universidad de Malaga, Spain

Address correspondence to:

Dr. Pedro Valdivielso

Departamento de Medicina y Dermatología

Facultad de Medicina

Boulevard Luis Pasteur 10

29010 Malaga, Spain.

Phone: +34 952131615; Fax +34 952131511. E-mail: [valdivielso@uma.es](mailto:valdivielso@uma.es)

Conflict of interests: none.

Funding: This study was partly financed by a grant from PAIDI (*Plan Andaluz de Investigación, Desarrollo e Innovación*) 159.

**ABSTRACT**

**Background:** Severe hypertriglyceridemia with an accumulation of chylomicrons and triglyceride figures >1000 mg/dL can cause acute pancreatitis, a potentially fatal complication. The option of rapid reduction in triglyceride concentrations is attractive and possible with plasmapheresis.

**Methods:** We present the results of an analysis of 11 patients admitted to the intensive care unit with severe hypertriglyceridemic pancreatitis and treated with plasmapheresis. The procedure was repeated until serum triglycerides were below 1000 mg/dL. We recorded anthropometric, clinical data as well as final outcome.

**Results:** In eight patients a single plasma exchange was sufficient to reduce triglyceride figures <1000 mg/dL. Only three patients died, all with the worst severity indexes and who experienced most delay before the procedure.

**Conclusions:** Our results, together with a review of the literature, confirm the need for a randomized clinical trial to compare conventional treatment vs. plasmapheresis in patients with severe hypertriglyceridemic pancreatitis.

**Keywords:** plasmapheresis, acute pancreatitis, severe hypertriglyceridemia, hypertriglyceridemic pancreatitis.

## INTRODUCTION

Hypertriglyceridemia is associated with severe complications, such as acute pancreatitis [1-4], as well as being a cardiovascular risk factor [5, 6]. The usual treatment of hypertriglyceridemia includes dietary restrictions and lipid-lowering drugs [7]. However, situations exist that may require the urgent rapid and efficient reduction in blood levels of triglycerides. In these situations plasmapheresis has proven a valid and safe technique for the treatment of severe hypertriglyceridemia complicated by acute pancreatitis [8]. In addition, plasma exchange has been used to prevent acute pancreatitis in patients with severe hypertriglyceridemia who don't respond to conventional diets and drugs, as a multicenter study recently showed [9].

Plasmapheresis is the procedure by which plasma is separated from the blood and processed to eliminate certain components. The plasma is then usually reinfused back into the patient, though on occasions it may be completely eliminated and replaced by an isovolumetric substance. Plasmapheresis is a simple extracorporeal process that can be carried out as either an emergency or programmed procedure. It is particularly indicated in neurological, hematological and rheumatologic diseases and involves minimum adverse effects [10]. The filtering techniques in plasmapheresis include double or cascade filtration, where a first filter separates the whole blood from the plasma, with the plasma then being passed through a second filter with smaller pores that prevent the passage of high-molecular weight molecules, in this case triglycerides. The benefits may go beyond the mere reduction in triglyceride levels, and include, for example, the removal of excess proteases and replacement of consumed protease inhibitors [8].

Experience in the treatment of hypertriglyceridemia with apheresis is still scarce. Most of the literature refers to single cases [11-16], though a recent excellent review summarizing the six reports involving more than ten patients shows that the technique results in drastic reductions of 60% in serum triglycerides in just a few hours [17]. Due to the lack of controlled and randomized trials in this field, the American Society for Apheresis recommendation for the procedures is only Grade 2C [18].

The aim of this study is to describe the usefulness of plasmapheresis in critical patients admitted to our center with a diagnosis of hyperlipidemic pancreatitis.

## METHODS

This observational, retrospective study comprised patients admitted to the Intensive Care Unit of the Hospital Universitario Virgen de la Victoria, Malaga, with lipidemic pancreatitis and who were treated with plasmapheresis between 1 January 2007 and 31 December 2011. In addition to serum triglyceride concentrations >1000 mg/dL, at the time of admission to the emergency department the patients had to fulfill clinical (suggestive abdominal pain), analytical (elevated

serum amylase and lipase or urine amylase three times the upper limit of normal) and radiological (abdominal CT) criteria of acute pancreatitis.

We gathered information on demographic data, a family history of dyslipidemia, and a personal history of dyslipidemia, medical treatment of dyslipidemia, diabetes, hypertension, previous episodes of pancreatitis, alcohol consumption, and smoking, as well as biochemical and hematological data. The patients were classified for severity according to their APACHE II [19, 20], the Ranson criteria [21] and Balthazar score [22].

The plasmapheresis sessions were done using Prismaflex (Prismaflex TPE 2000, Gambro Industries, Hospal S.A. Intensive Care, Barcelona, Spain). The exchange volume was adjusted according to the formula  $[1 - (\text{Hematocrit}/100)] \times \text{Weight} \times 0.07$  [23]. In general, two liters of plasma were exchanged per session, with the procedure lasting about three hours. The replacement was done with a 5% albumin solution. The serum triglycerides were measured again six hours after the procedure, which was repeated if the figure was greater than 1000 mg/dL.

For each patient data were recorded on the number of plasmapheresis sessions, the exchange volume, the replacement solution, procedure time, complications or adverse effects during the procedure, as well as any other procedures associated with the stay in the Intensive Care Unit (need for mechanical ventilation, vasoactive drugs, hemofiltration). A record was also made of other complications, ICU stay, onset of respiratory distress syndrome, state of the patient on discharge from the ICU, follow-up after ICU discharge, triglyceride levels at hospital discharge, and hospital stay.

The variables were analyzed using SPSS 17.0. The qualitative variables are shown as number of cases (%) and the quantitative variables as means, with the standard deviation when relevant.

## RESULTS

The study included 11 patients (see Table 1). Their mean age was 40.6 years (range: 27 – 51 years), and 6 (54%) were men. The most usual personal history was alcohol consumption, in 8 patients (72%), followed by prior primary hypertriglyceridemia in 5 (45%), hypertension in 3 (27%) and type 2 diabetes mellitus in 2 (18%). Only one of the patients with hypertriglyceridemia was taking lipid-lowering drugs prior to the episode (Gemfibrozil); that patient was taking also estrogens as birth-control pill before the attack. In six patients who have assessed body-mass-index at admission, the median value was 28.1 kg/mt<sup>2</sup> (interquartile range 23.1-30.0). All subject with type 2 diabetes were treated with insulin infusion to keep blood glucose < 180 mg/dL avoiding hypoglycaemia.

Most of the patients (72%, 8 patients) had acute grade E pancreatitis, according to the Balthazar classification. Only 2 patients had one Ranson criteria at the first evaluation, 3 had

two criteria, 2 had three and 4 had four criteria. The median APACHE II was 13 (IQR 9-18), corresponding to an expected mortality of 24.7%.

Eight (72.7%) patients received one plasmapheresis session, 2 (18.2%) received two sessions, and just one (9.1%) patient required three sessions. At the start of the plasmapheresis sessions, the median (interquartile range) triglyceride concentration was 2138 (1338-2540) mg/dL and at the end it was 395 (335-485) mg/dL, representing a reduction of 81% (69-84). All the patients attained triglyceride concentrations <1000 mg/dL by the end of the procedure (Figure 1), and the level at hospital discharge was 173 (96-454) mg/dL.

Tolerance to the plasmapheresis was good; three cases had hypervolemia which was successfully treated with IV furosemide. Ten of the 11 patients experienced some type of complication during their ICU stay; 5 had ARDS of whom 4 required mechanical ventilation for 8 days; 4 patients needed continuous venovenous hemofiltration due to renal failure, which was completely reversed in 3 patients. Three patients died during their ICU stay, one of them after 17 days due to severe nosocomial pneumonia and the other two, after 52 and 53 days, due to multiple organ failure syndrome. All patients who died had necrotic-hemorrhagic pancreatitis. Compared with those who survived, those who died had significantly more Ranson criteria on admission [median 4 (IQR 4-4) vs. median 2.5 (IQR 2.0-3.0),  $p < 0.05$ ] and a tendency towards a higher APACHE II score [median 18 (IQR 15-20) vs. median 11 (IQR 8.2-15),  $p = 0.08$ ] and lower pre-plasmapheresis triglyceride levels (median 1338 (IQR 1314-1863) vs. 2230 (IQR 1994-2689),  $p = 0.08$ ) (Figure 2). Analysis of the time between symptom onset and plasmapheresis showed no significant differences, as the median time was 55 hours (IQR 22-118) in those who died and 49 (IQR 29-59) in those who survived.

## DISCUSSION

Our series provides data on 11 consecutive patients who underwent plasmapheresis due to acute pancreatitis and severe hypertriglyceridemia. This sample can be considered representative of this situation as more patients were male, most were in their 30s or 40s, a high percentage consumed alcohol and two out of eleven had type 2 diabetes mellitus. These figures are concordant with two previous series from our center [4, 24] and those of other groups [25-28]. Plasmapheresis proved very efficient and after the procedure all the patients had triglyceride levels <1000 mg/dL, a figure below which the concentration of chylomicrons is scarce and the risk of pancreatitis exceptional [24, 29]. Only a few adverse effects were noted, and limited to just three episodes of hypervolemia, which were successfully treated with diuretics. However, plasmapheresis was unable to prevent a fatal outcome in three of the 11 patients treated. Various different factors may be involved in this situation. First, the three patients who died were admitted to the ICU with the most advanced grade of acute pancreatitis, as they all had four Ranson criteria simultaneously, a grade E on the Balthazar scale and an APACHE-II score >15.

These results are comparable to those of other series, as mortality in patients with hypertriglyceridemic pancreatitis and three or more Ranson criteria was 15-30% [30]; and in another series, an APACHE II score >8 increased mortality to 45% [31]. Besides, other authors did not find a clear relation between the use of plasmapheresis and either improvement in APACHE II scores, length of stay in either the ICU or overall hospital length of stay or in the prevention of complications secondary to severe pancreatitis [32]. Furthermore, it was not found differences in morbidity and mortality among patients with acute hypertriglyceridemic pancreatitis between those treated with plasma exchange and those treated conventionally [30].

Secondly, given that autodigestion is the pathogenic mechanism characterizing acute pancreatitis, it is possible that once it is triggered by the sudden rise in chylomicrons and/or alcohol consumption, the delay between symptom onset and plasmapheresis could have a relevant impact on the outcome. To this extent, a notable aspect of our study is that the patients who died had lower pre-treatment triglyceride concentrations than those who survived. Though other factors causing the acute pancreatitis may explain the differences, such as alcohol intake, these lower triglyceride levels may be explained by a greater delay in reaching the hospital and being treated. Assuming that the symptoms of hypertriglyceridemic pancreatitis start when triglyceride levels are at their peak, these levels will then fall as the patient fasts due to abdominal pain and vomiting. In fact, most of the patients at our center with hypertriglyceridemic pancreatitis treated conventionally have triglyceride levels <1000 mg/dL 24 hours after admission [4]. This therefore suggests that those patients who died perhaps experienced a greater delay to treatment and may not have been able to benefit from it. Nevertheless, in our series there was no relation between the number of hours of symptoms and the time the procedure was performed.

Four basic mechanisms of plasmapheresis have been proposed to explain the benefit of the procedure, as it has been recently published [33]. In addition to remove the offending agent (chylomicrons), the procedure is also able to remove proteases and pro-inflammatory cytokines as well to reduce hyperviscosity. If fresh frozen plasma is exchange, then lipoprotein lipase (LPL) and apolipoprotein C-II might enhance the endogenous lipolysis. In our opinion, this is unlikely, because pre heparin samples contain only small and mainly inactive amounts of LPL [34] and the addition of apolipoprotein C-II reduce plasma triglycerides only in those subjects with apo C-II deficiency, an extraordinary rare disorder causing familial chylomicronemia [35]. In fact, plasma apo C-II levels are greater in hypertriglyceridemic patients than in controls [24].

This study has certain limitations. It was a retrospective-descriptive study, with a small sample size as the cases all came from a single center, and there was no control group. Furthermore, the genetic background was not assessed.

In conclusion, hypertriglyceridemic acute pancreatitis can be treated with plasmapheresis, with very few adverse effects. Treatment success seems to depend on the intensity of the hypertriglyceridemia. As the indication for plasmapheresis is not supported by randomized clinical trials, multicenter studies are needed in order to provide a sufficient sample size and in which the patients are randomized to receive either conventional treatment or plasmapheresis. This will enable determination of the benefits in terms of hospital morbidity and mortality derived from the procedure. Up to then, we believe that plasmapheresis should be offer to patients with severe hypertriglyceridemic acute pancreatitis as early as possible.

### LEARNING POINTS

- Severe hypertriglyceridemia with chylomicronemia is associated to acute pancreatitis, a potentially fatal complication.
- Plasmapheresis is able to reduce in few hours high serum triglyceride concentrations, removing from circulation chylomicrons
- Plasmapheresis should be considered for the treatment of severe acute hypertriglyceridemic pancreatitis if available at the earliest stages of the disease.

Patient	Age	Time <sup>2</sup>	Gender	Comorbidities	Balthazar	Ranson	APACHE II	TG <sub>1</sub>	Sessions
1	47	53	Female	HTG. HTN. DM.	E	1	13	2173	1
2	46	45	Male	HTG. Alcohol.	E	2	20	2132	1
3	36	18	Female	HTG. DM	E	2	8	2288	1
4	27	61	Female	Alcohol	E	4	15	1949	2
5	29	83	Male	HTG	C	3	12	2739	1
6 <sup>1</sup>	48	22	Male	Alcohol	E	4	20	1863	3
7 <sup>1</sup>	44	55	Male	Alcohol	E	4	15	1314	2
8	42	29	Female	Acohol	C	2	5	2540	1
9 <sup>1</sup>	43	118	Male	Alcohol	E	4	18	1338	1
10	34	32	Male	HTN. Alcohol	E	3	10	1290	1
11	51	54	Female	HTG. HTN. Alcohol	D	1	9	5238	1

<sup>1</sup> Patient died

<sup>2</sup> Time (hours) since first symptom to plasmapheresis

HTG: hypertriglyceridemia.

HTN: hypertension.

DM: diabetes mellitus.

TG<sub>1</sub>: Serum triglycerides (mg/dL) at admission in emergency ward.

## REFERENCES

- 1 Brown WV, Brunzell JD, Eckel RH, Stone NJ. Severe hypertriglyceridemia. *J Clin Lipidol* 2012; **6**: 397-408.
- 2 Chait A, Brunzell JD. Chylomicronemia syndrome. *Adv Intern Med* 1992; **37**: 249-73.
- 3 Brunzell JD, Bierman EL. Chylomicronemia syndrome. Interaction of genetic and acquired hypertriglyceridemia. *Med Clin North Am* 1982; **66**: 455-68.
- 4 Ivanova R, Puerta S, Garrido A, *et al.* Triglyceride levels and apolipoprotein E polymorphism in patients with acute pancreatitis. *Hepatobiliary Pancreat Dis Int* 2012; **11**: 96-101.
- 5 Valdivielso P, Sánchez-Chaparro MA, Calvo-Bonacho E, *et al.* Association of moderate and severe hypertriglyceridemia with obesity, diabetes mellitus and vascular disease in the Spanish working population: results of the ICARIA study. *Atherosclerosis* 2009; **207**: 573-8.
- 6 Neil HA, Cooper J, Betteridge DJ, *et al.* All-cause and cardiovascular mortality in treated patients with severe hypertriglyceridaemia: A long-term prospective registry study. *Atherosclerosis* 2010; **211**: 618-23.
- 7 Chapman MJ, Ginsberg HN, Amarenco P, *et al.* Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. *European Heart Journal* 2011; **32**: 1345-61.
- 8 Ewald N, Kloer HU. Severe hypertriglyceridemia: an indication for apheresis? *Atheroscler Suppl* 2009; **10**: 49-52.
- 9 Stefanutti C, Di Giacomo S, Vivenzio A, *et al.* Therapeutic plasma exchange in patients with severe hypertriglyceridemia: a multicenter study. *Artif Organs* 2009; **33**: 1096-102.
- 10 Salazar Ramirez C, Daga Ruiz D, Cota Delgado F, Fernández Aguirre C, Fernández Añon JM, Garcia Fernández JM. [Utility of plasmapheresis in intensive care]. *Med Intensiva* 2010; **34**: 74-8.
- 11 Betteridge DJ, Bakowski M, Taylor KG, Reckless JP, de Silva SR, Galton DJ. Treatment of severe diabetic hypertriglyceridaemia by plasma exchange. *Lancet* 1978; **1**: 1368.
- 12 Hovland A, Hardersen R, Mollnes TE, Lappegård KT. Selective whole blood lipoprotein apheresis to prevent pancreatitis in drug refractory hypertriglyceridemia. *JOP* 2010; **11**: 467-9.
- 13 Izquierdo-Ortiz MJ, Abaigar-Luquin P. Severe hypertriglyceridaemia. Treatment with plasmapheresis. *Nefrologia* 2012; **32**: 417-8.

- 14 Manrique Franco K, Sánchez-Vilar Burdiel O, Aragón Valera C, Sánchez Fernández MS, Rovira Loscos A. [Plasmapheresis as treatment for severe hypertriglyceridemia]. *Endocrinol Nutr* 2011; **58**: 319-20.
- 15 Resheq YJ, Rinninger F, Lohse AW, Schramm C. An unusual cause of hypertriglyceridemic acute pancreatitis. *Am J Gastroenterol* 2012; **107**: 957-9.
- 16 Stefanutti C, Di Giacomo S, Labbadia G. Timing clinical events in the treatment of pancreatitis and hypertriglyceridemia with therapeutic plasmapheresis. *Transfus Apher Sci*. England: 2011 Elsevier Ltd. 2011; 3-7.
- 17 Ewald N, Kloer HU. Treatment options for severe hypertriglyceridemia (SHTG): the role of apheresis. *Clin Res Cardiol Suppl* 2012; **7**: 31-5.
- 18 Szczepiorkowski ZM, Winters JL, Bandarenko N, *et al*. Guidelines on the use of therapeutic apheresis in clinical practice—Evidence-based approach from the apheresis applications committee of the American Society for Apheresis. *Journal of Clinical Apheresis* 2010; **25**: 83-177.
- 19 Chatzicostas C, Roussomoustakaki M, Vardas E, Romanos J, Kouroumalis EA. Balthazar computed tomography severity index is superior to Ranson criteria and APACHE II and III scoring systems in predicting acute pancreatitis outcome. *Journal of clinical gastroenterology* 2003; **36**: 253-60.
- 20 Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. *Crit Care Med* 1985; **13**: 818-29.
- 21 Ranson JH. Etiological and prognostic factors in human acute pancreatitis: a review. *The American Journal of Gastroenterology* 1982; **77**: 633-8.
- 22 Balthazar EJ, Robinson DL, Megibow AJ, Ranson JH. Acute pancreatitis: value of CT in establishing prognosis. *Radiology* 1990; **174**: 331-6.
- 23 Ismail N, Kiproff D, Hakim R. Plasmapheresis. In: Daudirgas J, Blake P, Ing T, eds, *Handbook of dialysis*. Philadelphia: Lippincott Williams & Wilkins. 2007; 275-99.
- 24 Coca-Prieto I, Valdivielso P, Olivecrona G, *et al*. Lipoprotein lipase activity and mass, apolipoprotein C-II mass and polymorphisms of apolipoproteins E and A5 in subjects with prior acute hypertriglyceridaemic pancreatitis. *BMC gastroenterology* 2009; **9**: 46.
- 25 Linares CL, Pelletier AL, Czernichow S, *et al*. Acute pancreatitis in a cohort of 129 patients referred for severe hypertriglyceridemia. *Pancreas* 2008; **37**: 13-2.
- 26 Athyros VG, Giouleme OI, Nikolaidis NL, Vasiliadis TV, Bouloukos VI, Kontopoulos AG, Eugenidis NP. Long-term follow-up of patients with acute hypertriglyceridemia-induced pancreatitis. *J Clin Gastroenterol* 2002; **34**: 472-5.

- 27 Anderson F, Thomson SR, Clarke DL, Buccimazza I. Dyslipidaemic pancreatitis clinical assessment and analysis of disease severity and outcomes. *Pancreatology*. Switzerland: 2009 S. Karger AG, Basel. 2009; 252-7.
- 28 Deng L, Xue P, Xia Q, Yang X, Wan M. Effect of admission hypertriglyceridemia on the episodes of severe acute pancreatitis. *World J Gastroenterol* 2008; **14**: 4558-61.
- 29 Tsuang W, Navaneethan U, Ruiz L, Palascak JB, Gelrud A. Hypertriglyceridemic pancreatitis: presentation and management. *The American Journal of Gastroenterology* 2009; **104**: 984-91.
- 30 Chen JH, Yeh JH, Lai HW, Liao CS. Therapeutic plasma exchange in patients with hyperlipidemic pancreatitis. *World J Gastroenterol* 2004; **10**: 2272-4.
- 31 Gubensek J, Buturovic-Ponikvar J, Marn-Pernat A, Kovac J, Knap B, Premru V, Ponikvar R. Treatment of hyperlipidemic acute pancreatitis with plasma exchange: a single-center experience. *Ther Apher Dial*. Australia. 2009; 314-7.
- 32 Syed H, Bilusic M, Rhondla C, Tavarria A. Plasmapheresis in the treatment of hypertriglyceridemia-induced pancreatitis: A community hospital's experience. *J Clin Apher* 2010; **25**: 229-34.
- 33 Stefanutti C, Labbadia G, Morozzi C. Severe Hypertriglyceridemia-Related Acute Pancreatitis. *Therapeutic Apheresis and Dialysis* 2013; **17**: 130-7.
- 34 Tornvall P, Olivecrona G, Karpe F, Hamsten A, Olivecrona T. Lipoprotein Lipase Mass and Activity in Plasma and Their Increase After Heparin Are Separate Parameters With Different Relations to Plasma Lipoproteins. *Arterioscler Thromb Vasc Biol* 1995; **15**: 1086-93.
- 35 Brunzell JD, Deeb SS. Familial Lipoprotein Lipase deficiency, apo C-II deficiency and hepatic lipase deficiency. In: Scriver CR, Beaudet BL, Sly WS, Valle D, eds, *The Metabolic & Molecular Bases of Inherited Disease*. New York: McGraw-Hill. 2001; 2789.

## LEGENDS TO THE FIGURES

Figure 1: Changes in serum triglyceride levels after plasmapheresis sessions and at hospital discharge.

Figure 2: Median and interquartile range of serum triglyceride levels at admission according to vital outcome.